NASDAQ: PMNPromis Neurosciences Inc Stock
$10.54+0.16 (+1.54%)
Updated Jun 18, 2026
PMN Price
$10.54
Fair Value Price
$0.00
Market Cap
$94.52M
52 Week Low
$6.27
52 Week High
$39.75
P/E
-0.6x
P/B
1.56x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$40.62M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$36M
Beta
0.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PMN Overview
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PMN's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PMN
Ranked#345 of 465
Ranked#345 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important PMN news, forecast changes, insider trades & much more!
PMN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PMN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PMN ($10.54) is overvalued by 424,638.31% relative to our estimate of its Fair Value price of $0.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PMN ($10.54) is not significantly undervalued (424,638.31%) relative to our estimate of its Fair Value price of $0.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PMN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PMN due diligence checks available for Premium users.
Valuation
PMN fair value
Fair Value of PMN stock based on Discounted Cash Flow (DCF)
Price
$10.54
Fair Value
$0.00
Overvalued by
424,638.31%
PMN ($10.54) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PMN ($10.54) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PMN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PMN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.6x
Industry
15.77x
Market
9.47x
PMN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.56x
Industry
4.95x
PMN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PMN's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.2M
Profit Margin
0%
PMN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$67.4M
Liabilities
$6.7M
Debt to equity
0.11
PMN's short-term assets ($65.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PMN's short-term assets ($65.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PMN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.4M
Investing
$0.0
Financing
$70.1M
PMN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PMN vs Biotech Stocks
Promis Neurosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.